Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX)
CUSIP: 03237H101
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 109,540,561
- Total 13F shares
- 109,720,694
- Share change
- +28,023,346
- Total reported value
- $1,491,122,082
- Put/Call ratio
- 37%
- Price per share
- $13.59
- Number of holders
- 168
- Value change
- +$396,029,872
- Number of buys
- 99
- Number of sells
- 67
Quarterly Holders Quick Answers
What is CUSIP 03237H101?
CUSIP 03237H101 identifies AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 03237H101:
Top shareholders of AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
|
Company |
8.2%
|
8,952,365
|
$121,662,640 | +$14,650,251 | 30 Sep 2025 | |
| ALS Invest 1 B.V. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
5,895,280
|
$96,258,721 | — | 06 Jul 2022 | |
| Morningside Venture Investments Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,997,302
|
$81,596,447 | — | 15 Aug 2023 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
8%
|
8,800,000
|
$56,408,000 | — | 30 Jun 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
5.4%
|
5,943,812
|
$38,099,835 | — | 30 Jun 2025 | |
| Point72 Asset Management, L.P. |
13D/G
13F
|
Company |
2.6%
|
2,801,636
|
$38,074,233 | -$26,039,432 | 30 Sep 2025 | |
| DRAGSA 96 LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,300,000
|
$37,554,630 | — | 11 Jan 2022 | |
| BlackRock, Inc. |
13F
|
Company |
5%
|
5,510,189
|
$35,320,311 | — | 30 Jun 2025 | |
| VIKING GLOBAL INVESTORS LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,850,940
|
$30,222,333 | — | 08 Sep 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.1%
|
4,498,028
|
$28,832,360 | — | 30 Jun 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
3%
|
3,260,570
|
$20,900,254 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
2.8%
|
3,048,019
|
$19,537,802 | — | 30 Jun 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
2.7%
|
2,934,405
|
$18,809,536 | — | 30 Jun 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
2%
|
2,160,000
|
$13,845,600 | — | 30 Jun 2025 | |
| Almitas Capital LLC |
13F
|
Company |
1.9%
|
2,122,597
|
$13,605,847 | — | 30 Jun 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
1.8%
|
2,000,000
|
$12,820,000 | — | 30 Jun 2025 | |
| Panacea Innovation Ltd |
13D/G
|
Panacea Venture Healthcare Fund II, L.P. |
2.6%
|
2,200,000
|
$11,792,000 | $0 | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
1,692,413
|
$10,850,718 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.4%
|
1,512,058
|
$9,692,292 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
1,297,982
|
$8,320,065 | — | 30 Jun 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.2%
|
1,264,997
|
$8,108,631 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
1.1%
|
1,253,344
|
$8,033,935 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.1%
|
1,242,927
|
$7,967,162 | — | 30 Jun 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1.1%
|
1,225,000
|
$7,852,250 | — | 30 Jun 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
1.1%
|
1,205,101
|
$7,724,697 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.1%
|
1,200,290
|
$7,693,859 | — | 30 Jun 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
1.1%
|
1,154,485
|
$7,400,249 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.92%
|
1,008,909
|
$6,467,107 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.75%
|
820,164
|
$5,257,251 | — | 30 Jun 2025 | |
| Margaret Olinger |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
320,685
mixed-class rows
|
$5,178,792 | — | 27 Dec 2023 | |
| Aberdeen Group plc |
13F
|
Company |
0.67%
|
738,657
|
$4,734,791 | — | 30 Jun 2025 | |
| PFM Health Sciences, LP |
13F
|
Company |
0.67%
|
732,256
|
$4,693,761 | — | 30 Jun 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.59%
|
650,000
|
$4,166,500 | — | 30 Jun 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.59%
|
646,443
|
$4,143,699 | — | 30 Jun 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.56%
|
616,919
|
$3,954,451 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.54%
|
588,411
|
$3,771,715 | — | 30 Jun 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.54%
|
586,883
|
$3,761,920 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.52%
|
569,083
|
$3,645,000 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.51%
|
558,846
|
$3,582,203 | — | 30 Jun 2025 | |
| Patrick D. Yeramian |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
239,375
mixed-class rows
|
$3,357,139 | — | 09 Jan 2024 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.46%
|
499,764
|
$3,203,487 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.44%
|
486,893
|
$3,120,984 | — | 30 Jun 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.43%
|
470,000
|
$3,012,700 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.41%
|
451,808
|
$2,896,090 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.4%
|
438,026
|
$2,807,747 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.36%
|
396,200
|
$2,539,642 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.34%
|
373,739
|
$2,395,083 | — | 30 Jun 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.29%
|
313,200
|
$2,007,612 | — | 30 Jun 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.26%
|
288,618
|
$1,850,040 | — | 30 Jun 2025 | |
| Alpha Wave Global, LP |
13F
|
Company |
0.25%
|
275,842
|
$1,768,147 | — | 30 Jun 2025 |
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) as of Q3 2025
As of 30 Sep 2025,
Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) was held by
168 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
109,720,694 shares.
The largest 10 holders included
FMR LLC, PERCEPTIVE ADVISORS LLC, BlackRock, Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., TCG Crossover Management, LLC, VANGUARD GROUP INC, Saturn V Capital Management LP, Commodore Capital LP, First Light Asset Management, LLC, and Point72 Asset Management, L.P..
This page lists
168
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
131
Q3 2025 holders
168
Holder diff
37
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.